Please assess the completion status of the following clinical trial:

Trial Title: LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* male or female patient aged 18 years or older;~* histologically or cytologically confirmed, locally advanced and/or metastatic NSCLC of stage IIIB or IV or recurrent NSCLC;~* relapse or failure of one first line prior chemotherapy;~* at least one target tumour lesion that has not been irradiated within the past three months and that can accurately be measured ;~* life expectancy of at least three months;~* Eastern Cooperative Oncology group (ECOG) score of 0 or 1;~* patient has given written informed consent~Exclusion criteria:~* more than one prior chemotherapy regimen for advanced and/or metastatic or recurrent NSCLC;~* more than one chemotherapy treatment regimen (either neoadjuvant or adjuvant or neoadjuvant plus adjuvant) prior to first line chemotherapy;~* previous therapy with other VEGFR inhibitors (other than bevacizumab) or docetaxel for treatment of NSCLC;~* persistence of clinically relevant therapy related toxicities from previous chemotherapy and/or radiotherapy;~* treatment with other investigational drugs or other anti-cancer therapy or treatment in another clinical trial within the past four weeks before start of - therapy or concomitantly with this trial ;~* radiotherapy (except extremities and brain) within the past three months prior to baseline imaging;~* active brain metastases or leptomeningeal disease;~* radiographic evidence of cavitary or necrotic tumours;~* centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels;~* history of clinically significant haemoptysis within the past 3 months;~* therapeutic anticoagulation (except low dose heparin) or antiplatelet therapy;~* history of major thrombotic or clinically relevant major bleeding event in the past 6 months;~* known inherited predisposition to bleeding or thrombosis;~* significant cardiovascular diseases ;~* inadequate safety laboratory parameters;~* significant weight loss (\> 10 %) within the past 6 weeks;~* current peripheral neuropathy greater than CTCAE grade 2 except due to trauma;~* preexisting ascites and/or clinically significant pleural effusion;~* major injuries and/or surgery within the past ten days prior to randomisation with incomplete wound healing;~* serious infections requiring systemic antibiotic therapy;~* decompensated diabetes mellitus or other contraindication to high dose corticosteroid therapy;~* gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug;~* active or chronic hepatitis C and/or B infection;~* serious illness or concomitant non-oncological disease or laboratory abnormality that may increase the risk associated with study participation or study drug administration;~* patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for at least twelve months after end of active therapy;~* pregnancy or breast feeding;~* psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule;~* patients unable to comply with the protocol;~* active alcohol or drug abuse;~* other malignancy within the past three years other than basal cell skin cancer, or carcinoma in situ of the cervix;~* any contraindications for therapy with docetaxel;~* history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80);~* hypersensitivity to BIBF 1120 and/or the excipients of the trial drugs;~* hypersensitivity to contrast media

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBF 1120 plus docetaxel (Type: EXPERIMENTAL): BIBF 1120 2 times daily along with standard therapy of docetaxel
- Placebo plus docetaxel (Type: PLACEBO_COMPARATOR): Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete